Divine Aleru, Microbiome Signatures Research Coordinator

This study investigates the effects of ketogenic and high-fat diets on gut microbial composition and ovarian cancer progression in mice. It shows that high-fat diets increase tumor growth and disrupt microbial diversity, highlighting the potential role of diet in cancer therapy and prevention.

This review examines the relationship between diet and ovarian cancer risk, finding that animal fats and dairy are linked to higher risk, while vegetables and bioactive compounds may offer protective benefits, although results are inconsistent across studies.

This case-control study highlights the significant role of diet in ovarian cancer risk, with high vegetable and fruit intake reducing risk, while animal fats and salted vegetables increase it. Fried and smoked foods also contribute to a higher risk.

This review underscores the importance of diet and physical activity in modulating the gut microbiome of cancer patients. Diets like fiber-rich and Mediterranean diets show promise in improving cancer treatment outcomes. Exercise also enhances microbial diversity and immune function, potentially improving patient quality of life.

Probiotics were shown to significantly reduce cancer cell proliferation, promote apoptosis, and inhibit migration in breast and ovarian cancer cells, suggesting their potential as adjunctive cancer therapies.

This review maps advances in ovarian cancer management, from surgery and chemotherapy to targeted and emerging therapies, and highlights a need to integrate microbiome insights.

This review analyzes the global epidemiology and risk factors of ovarian cancer, emphasizing the role of genetic predispositions, reproductive factors, and lifestyle choices. It highlights the disparities in incidence and mortality rates across regions and calls for better prevention and early detection strategies.

This review discusses ovarian cancer diagnosis, molecular characteristics, and treatment strategies, emphasizing the role of targeted therapies like PARP inhibitors and immunotherapy, with a focus on personalized treatment approaches based on genetic and molecular tumor profiles.

This review covers the epidemiology, genetics, and molecular mechanisms of ovarian cancer, focusing on the role of estrogen receptors and genetic mutations such as BRCA1/2. It emphasizes the importance of genetic testing and the potential of targeted therapies, including PARP inhibitors, for improving patient outcomes.

This review discusses liquid biopsy techniques for early ovarian cancer detection, focusing on circulating tumor cells, cell-free DNA, and extracellular vesicles. It highlights their potential to improve sensitivity, specificity, and prognosis prediction, providing a promising avenue for non-invasive cancer screening.

This review explores the molecular mechanisms of ovarian cancer metastasis, focusing on the role of stromal cells and the metastatic routes—passive dissemination and hematogenous spread—while discussing therapeutic implications for targeting both cancer cells and the tumor microenvironment.

Primary Ovarian Insufficiency (POI) is a medical condition in which a woman’s ovaries stop functioning normally before the age of 40. This leads to reduced estrogen production and irregular menstrual cycles, which may eventually result in infertility and early menopause-like symptoms. POI can occur due to various reasons, including genetic factors, autoimmune disorders, chemotherapy, or unknown causes. Though often misunderstood and misdiagnosed, POI can significantly impact a woman’s physical and emotional well-being. Early diagnosis and appropriate treatment, including hormone replacement therapy (HRT) and fertility interventions, can help manage symptoms, improve quality of life, and in some cases, restore fertility.

This study explored the role of hormone replacement therapy (HRT) in reversing gut microbiome and serum metabolome alterations in women with premature ovarian insufficiency (POI), identifying potential therapeutic targets for microbiome-based interventions.

This review explores butyrate’s role as a modulator in gynecological diseases, including PCOS, endometriosis, and cancer, highlighting its potential as a therapeutic agent through immune modulation, inflammation reduction, and cancer inhibition.

This paper explores how gut microbiota dysbiosis contributes to premature ovarian failure (POF) and highlights potential therapeutic interventions targeting GM for better management of POF.

This review examines the relationship between gut microbiota and ovarian aging, highlighting microbial dysbiosis as a key factor in ovarian function decline. It explores microbiota-based therapies like FMT to delay ovarian aging and discusses the role of dietary and pharmacological interventions.

This study demonstrates the effectiveness of ultrasound-guided hUC-MSC exosome injection in restoring ovarian function and fertility in POI rat models, offering a new therapeutic approach for women with POI.

This study demonstrates that metformin protects against chemotherapy-induced ovarian failure by reducing inflammation, oxidative stress, and senescence in granulosa cells via the AMPK/PPAR-γ/SIRT1 pathway.

The review discusses the therapeutic use of hormone replacement therapy (HRT) for managing POI and early menopause, highlighting its benefits in preventing complications like osteoporosis, cardiovascular disease, and depression.

Amsel’s Criteria is a clinically established diagnostic method for bacterial vaginosis, offering a practical and accessible alternative to laboratory-based approaches. It evaluates four key clinical indicators, ensuring timely diagnosis and intervention in outpatient settings.

This study identifies 27 metabolites linked to primary ovarian insufficiency (POI), revealing novel metabolic pathways and offering insights into POI biomarkers and therapeutic targets.

This study identifies 33 serum metabolites, including N-acetylalanine, linked to an increased risk of primary ovarian insufficiency (POI), offering new insights into the disease’s genetic and metabolic causes.

This study identifies metabolic disruptions in POI, including altered amino acid and lipid metabolism. Key metabolites such as acetoacetate and HDCA were found to be potential biomarkers, shedding light on the oxidative stress and mitochondrial dysfunction involved in POI.

This study examines the metabolic profile of women with premature ovarian insufficiency, finding significant changes in lipid and glucose metabolism. The results underscore the importance of early metabolic screening and management to reduce cardiovascular and metabolic risks associated with POI.